Skip to main content
Contact Us
Subscribe
E-Edition
70°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Apnimed
Apnimed to Present at the Stifel Healthcare Conference
November 08, 2022
From
Apnimed
Via
Business Wire
Apnimed Announces Positive Topline Results for MARIPOSA Trial of AD109, Drug Candidate with the Potential to be the First Oral Therapy for Obstructive Sleep Apnea (OSA)
October 17, 2022
From
Apnimed
Via
Business Wire
Apnimed to Participate in the 2nd Annual Needham Biotech Private Company Virtual 1x1 Forum
October 12, 2022
From
Apnimed
Via
Business Wire
Apnimed Expands Senior Leadership Team by Appointing John Cronin, M.D., Senior Vice President, Clinical Development
October 05, 2022
From
Apnimed
Via
Business Wire
Apnimed to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference
August 04, 2022
From
Apnimed
Via
Business Wire
Apnimed Granted FDA Fast Track Designation for AD109, a Novel First-in-Class Oral Pharmacologic Combination for the Treatment of Obstructive Sleep Apnea (OSA)
June 28, 2022
From
Apnimed
Via
Business Wire
Apnimed Adds Ruoxi Hu, Ph.D., From Morningside Technology Advisory to Its Board of Directors
June 16, 2022
From
Apnimed
Via
Business Wire
Apnimed to Present at the Jefferies Healthcare Conference
June 06, 2022
From
Apnimed
Via
Business Wire
New Data Show Clinically Meaningful Improvements for Investigational Oral Pharmacologic Treatment AD504 in People With Obstructive Sleep Apnea
June 02, 2022
From
Apnimed
Via
Business Wire
Apnimed Announces $62.5 Million Series C Financing to Advance Development of Novel Pharmaceutical Treatments for Obstructive Sleep Apnea (OSA) and Related Sleep Disorders
May 04, 2022
From
Apnimed
Via
Business Wire
Apnimed to Participate in the 21st Annual Needham Virtual Healthcare Conference
April 05, 2022
From
Apnimed
Via
Business Wire
Apnimed to Participate in the SVB Leerink Global Healthcare Conference
February 07, 2022
From
Apnimed
Via
Business Wire
Apnimed to Present at the 40th Annual JP Morgan Healthcare Conference
January 06, 2022
From
Apnimed
Via
Business Wire
Apnimed Announces Dosing of First Patient in Phase 2 MARIPOSA Confirmatory Trial of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea (OSA)
December 16, 2021
From
Apnimed
Via
Business Wire
Apnimed Achieves Meaningful Results in Proof-of-Concept Crossover Study With Oral Therapeutic Candidates AD504 and AD182 for the Treatment of Obstructive Sleep Apnea
November 16, 2021
From
Apnimed
Via
Business Wire
Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment
October 13, 2021
From
Apnimed
Via
Business Wire
Apnimed Announces Positive Phase 2 Data (Study APC-004) Demonstrating Improvement in Measures of Obstructive Sleep Apnea and a Dose-Response with AD109, an Oral Pharmacologic Investigational Treatment for the Disease
October 13, 2021
From
Apnimed
Via
Business Wire
Apnimed Expands Executive Leadership Team Appointing Rob Rode Chief Commercial Officer
September 27, 2021
From
Apnimed
Via
Business Wire
Apnimed to Present at the Canaccord Genuity 41st Annual Growth Conference
August 06, 2021
From
Apnimed
Via
Business Wire
David P. White, M.D. Appointed Senior Vice President of Medical Affairs at Apnimed
July 27, 2021
From
Apnimed
Via
Business Wire
Apnimed to Present at the Ladenburg Thalmann Virtual Healthcare Conference
July 06, 2021
From
Apnimed
Via
Business Wire
Apnimed to Present at the Jefferies Virtual Healthcare Conference
May 25, 2021
From
Apnimed
Via
Business Wire
New Data Presented at American Thoracic Society Meeting Reinforces the Potential of an Oral Drug Combination Therapy for the Treatment of Obstructive Sleep Apnea
May 17, 2021
From
Apnimed
Via
Business Wire
Apnimed to Present at the 20th Annual Needham Virtual Healthcare Conference
April 12, 2021
From
Apnimed
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.